HOME NEWS EARNINGS RESULTS PICKS STRATEGY BLOG CONTACT SUBSCRIBE LOGIN SUBSCRIBE JOIN FREE
LOADING
Price Investing Group
← Back to Research Watchlist
VRDN
Viridian Therapeutics Inc
Healthcare Biotechnology · Colorado, USA · Reports in usd
Market Cap: $1.76B
Market Cap
$1.76B
Enterprise Val
$1.08B
P/E Ratio
-4.88
P/B Ratio
2.76
Trailing PEG (1Y)
-1.41
As Of
May 10, 2026

Overview & Key Metrics

Reporting period: Mar 31, 2026 · Q1 2026
Book Value$636.0M
Gross Margin100.00%
Profit Margin100.00%
Return on Equity-60.70%
Return on Assets-50.65%
Current Ratio15.15
Debt/Equity0.14
LT Debt/Equity0.14
Revenue Per Share0.00

Income Statement

Mar 31, 2026
Revenue$141.0K
Cost of Revenue$0.00
Gross Profit$141.0K
R&D$77.6M
SG&A$38.7M
Operating Expenses$116.3M
Operating Income-$116.2M
Interest Expense$3.5M
Tax Expense$0.00
Net Income-$104.9M
EPS (Basic)$-0.90
EPS (Diluted)$-0.90
EBIT-$101.4M
EBITDA-$101.3M
Consolidated Income-$104.9M
Non-Controlling Interests$0.00

Balance Sheet

Mar 31, 2026
Cash & Equivalents$176.3M
Accounts Receivable$0.00
Inventory$0.00
Current Assets$784.7M
LT Investments$0.00
Property, Plant & Equipment$3.4M
Intangibles$0.00
Non-Current Assets$4.3M
Total Assets$789.0M
Accounts Payable$13.3M
Current Debt$0.00
Current Liabilities$51.8M
LT Debt$86.5M
Non-Current Liabilities$101.2M
Total Liabilities$153.0M
Total Debt$86.5M
Retained Earnings-$1.44B
Shareholder Equity$636.0M
Shares Outstanding102,206,571

Cash Flow Statement

Mar 31, 2026
Operating Cash Flow-$119.7M
Investing Cash Flow$77.3M
Financing Cash Flow$6.4M
CapEx-$23.0K
Free Cash Flow-$119.7M
Depreciation & Amort.$121.0K
Stock-Based Comp$13.4M
Acquisitions / Disposals$0.00
Investment Activity$77.3M
Debt Issued/Repaid$0.00
Equity Issued/Repaid$6.4M
Dividends Paid$0.00
Net Change in Cash-$36.0M
Data cached · Meta cache · Daily cache · Statements cache · TTL 24h